Drugs / SapDM275
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07231094 | Nov 2025 → Nov 2027 expected | malignant pancreatic neoplasm | The Third Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SapDM275 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231094 ↗ |
| Modality | Vaccine | “SapDM275 tumor vaccine” NCT07231094 ↗ |
| Route | Intramuscular | “via intramuscular injection” NCT07231094 ↗ |